Iovance Biotherapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 total revenue was about $122 million, up 80% year over year and 22% sequentially; commercial melanoma therapy revenue was about $102 million, up 77% year over year and 12% sequentially.
- ProLutkin revenue was approximately $20 million, more than double the 2nd quarter level, as wholesaler ordering patterns realigned with demand.
- Gross margin reached approximately 60%, a record for the second consecutive quarter, compared with the previous record of 56%; year-to-date margin was 54%.
- Third-quarter R&D expenses were about $49 million, down approximately 16% sequentially and marking the 5th consecutive quarter of reduced R&D spending; selling, general, and administrative expenses were about $39 million, flat sequentially.
- The company reported approximately $382 million in cash, cash equivalents, short-term investments, and restricted cash on September 30th, and said its cash runway is expected to fund operations well into 2029.
- More than 1,000 commercial patients had been infused in the U.S. since launch, and the company had more than 100 authorized treatment centers (ATCs).
- In LUNG-202, lifelucel’s confirmed objective response rate was 24.6% among 69 patients with previously treated non-squamous metastatic non-small cell lung cancer; the company said durability was still maturing and safety improved with reduced-dose lymphodepletion while efficacy remained comparable.
- A biomarker-enriched non-squamous non-small cell lung cancer subgroup in LUNG-202 had a 59.1% response rate; a frontline subgroup had responses in 6 out of 7 patients.
- Updated soft tissue sarcoma results showed a confirmed response rate of 55.6% (5 of 9 patients) in UPS and DDLPS, including 2 ongoing responses more than a year from infusion.
- In a Phase 2 cohort in frontline advanced melanoma, 62.5% of patients responded, including complete responses; 29.2% had tumors disappear completely and not return, and median overall survival was not reached after more than 4 years of follow-up.
- In the ENDURANCE trial in previously treated metastatic serous endometrial cancer, the first 5 available patients had a 40% confirmed objective response rate and a 100% disease control rate.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the Iovance Biotherapeutics Third Quarter 2026 Conference Call. My name is Daniel, and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please note that this conference call is being recorded. I will now turn the call over to Jen Saunders, Senior Director, Investor Relations and Corporate Communications at Iovance. Jen, you may begin. Thank you, Daniel.
Good morning, and welcome to the Iovance webcast to discuss our third quarter 2026 financial results, business achievements, and corporate updates. This morning, we issued a press release that is available on our corporate website at iovance.com. This conference call will include forward-looking statements regarding Iovance's goals, business focus, business plans and transactions, revenue and revenue guidance, commercial activities, clinical trials and results, regulatory approvals, submissions, feedback and guidance, plans and strategies, research and preclinical activities, potential future applications of our technologies, manufacturing capabilities, payer interactions, licenses and collaborations, cash position, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements.
I will now turn the call over to Dr. Fred Vogt, Interim CEO and President.
Thank you, Jen. Good morning, everyone. Our third quarter delivered outstanding record-setting results for Iovance, with our highest ever revenue and margin and strong financial performance across the board. Total revenue of about $122 million surged 80% over the prior year. U.S. AMTAGVI revenue increased 77% over the prior year and crossed $100 million in a single quarter for the first time. We also passed an important landmark this quarter, with more than 1,000 commercial AMTAGVI patients now infused in the U.S. since launch. Based on this strong performance, we remain on track to achieve our full-year revenue guidance of $410 million-$420 million. Our authorized treatment center, or ATC network, continues to expand rapidly, and we fully expect to reach 110 or more authorized treatment centers by year-end.
Third quarter margin of about 60% also set a new all-time high for the second consecutive quarter, and we expect it to expand further over time. Our cash runway is now expected to fund operations well into 2029. This strong performance reflects the financial health of Iovance and the strong platform that we can build upon for upcoming launches. The third quarter and recent updates also reflect major progress across our TIL platform and pipeline programs. In metastatic non-small cell lung cancer, lifileucel continues to demonstrate a potentially best-in-class clinical profile. Earlier this year, the FDA granted fast-track designation based on the strength of our data and the high unmet need. Last week, we reported positive updated results from our registrational IOV-LUN-202 trial that included 69 patients with previously treated non-squamous metastatic non-small cell lung cancer.
The objective response rate, or ORR, by RECIST 1.1 was 24.6%, consistent with our prior results in 39 patients. Durability, while still maturing, was also consistent with our prior results and has already greatly surpassed the current standard of care, docetaxel, which has a response rate of only 12.8%, short durability of 5.6 months, and median overall survival of just 12.3 months. Safety in IOV-LUN-202 is consistent with our lifileucel experience to date across our clinical trials in multiple solid tumors. Encouragingly, the safety profile in IOV-LUN-202 improved using the updated reduced-dose lymphodepletion regimen. Efficacy, including durability, remains comparable and consistent in IOV-LUN-202 before and after the change to reduced-dose lymphodepletion. We will provide more details on IOV-LUN-202 as the study completes, with potential presentations at medical meetings in 2027. Looking ahead, we are confident in our plans to submit a supplemental Biologics License Application, or sBLA, in 2027.
We are completing enrollment in cohorts one and two with a target of approximately 80 patients for the sBLA. In parallel, we are advancing independent review committee assessments, FDA discussions, and other pre-submission activities, including preparation for a confirmatory trial. Alongside our latest IOV-LUN-202 update, we launched an innovative precision TIL strategy. We identified a biomarker-enriched subgroup of non-squamous non-small cell lung cancer patients in IOV-LUN-202 that demonstrated a remarkable 59.1% response rate. Nearly six in 10 patients showed a deep and durable response. These results are the foundation for POSITILITY, a first-in-class prospectively defined biomarker-enriched cohort with registrational intent that we will pursue in addition to our initial sBLA in 2027 in non-squamous non-small cell lung cancer. POSITILITY is targeting 80 patients and will begin enrollment this month, utilizing the existing IOV-LUN-202 site footprint to speed enrollment as part of a planned transition.
In 2027, we are also planning our OPTILISM trial to investigate this population in the frontline setting. Together, these biomarker-selected front and second-line settings represent a U.S. opportunity about 10 times the size of advanced melanoma. At the ESMO Congress in late October, two oral presentations showcased the broader potential for lifileucel to demonstrate deep, durable responses in soft tissue sarcomas and frontline advanced melanoma. Following one of the oral sessions at ESMO, this morning's press release included our most recent updates in soft tissue sarcoma. The confirmed ORR by RECIST 1.1 for lifileucel in refractory undifferentiated pleomorphic sarcoma, or UPS, and dedifferentiated liposarcoma, or DDLPS, has climbed to 55.6%, five of nine patients. Multiple durable responses have already been observed, including two ongoing more than a year from infusion.
Safety in the sarcoma trial is consistent with our lifileucel experience to date across our clinical trials in multiple solid tumors. These powerful results in heavily pretreated patients are the basis for SARATOGA, our registrational trial that is actively enrolling to support two approvals for lifileucel. After failing chemotherapy, second-line response rates are typically below 5%. Median survival is about nine to 10 months, and there are no approved immunotherapies. In recognition of this unmet need, as well as our initial results, the FDA granted fast-track designation in both UPS and DDLPS. In addition, we have aligned with the agency on the design and a potential accelerated approval pathway based on the SARATOGA trial, with 40 patients expected in each cohort and sBLA submissions planned for 2028 or 2029.
In our second oral session at ESMO, we focused on frontline advanced melanoma, where about half of patients do not achieve long-term benefit with today's standard combination checkpoint inhibitors. In our phase II cohort of frontline advanced melanoma, 62.5% of patients responded, including complete responses in 29.2% of patients where tumors disappeared completely and did not return. Median overall survival was not reached after more than four years of follow-up. Safety was consistent with the known safety profiles of one-time lifileucel and pembrolizumab. These results reinforce TILVANCE-301, our phase III trial enrolling in more than 80 sites and expanding, designed to support both the frontline approval and serve as the confirmatory trial for full U.S. approval of AMTAGVI.
In summary, Iovance is focused on growing revenue, expanding into new indications and markets, and broadening TIL therapy into solid tumor indications, including biomarker-selective populations that collectively represent tens of thousands of cancer patients with poor prognosis and limited available options. I am also thrilled to welcome our new Chief Medical Officer, Dr. Noah Berkowitz, to his first quarterly call at Iovance to discuss additional details about our pipeline. His valuable expertise in global drug development across cancer and blood disorders led to approvals for the CAR T-cell therapies Abecma and Breyanzi while at Bristol Myers Squibb. As the first and only company in the world to take TIL therapy from concept to commercial treatment, we are forging ahead with tremendous momentum toward profitability and long-term value for patients and shareholders alike. Corleen Roche, our Chief Financial Officer, will now highlight our financial results.
Thanks, Fred, and good morning, everyone. The third quarter was another record quarter for Iovance, combining strong revenue, record margin, and disciplined spending. Revenue is up 80% year over year. Margin is at an all-time high of 60%, and operating expenses reflected disciplined, intentional allocation of capital to our highest return priorities. Our cash runway is expected to fund operations well into 2029. Total revenue once again achieved a new quarterly record of about $122 million, up 80% year over year, as I mentioned, and 22% sequentially. AMTAGVI powered that revenue growth by reaching more patients than ever before. AMTAGVI sales of around $102 million represent a 77% increase year over year and a 12% increase sequentially, reflecting strong patient demand and broad adoption.
Proleukin revenue contributed approximately $20 million in the third quarter, more than double the second quarter level as wholesaler ordering patterns are realigning with AMTAGVI demand. As expected, the quality of our revenue remains high, with gross to net deductions around 1%, consistent with prior quarters. That high-quality revenue is flowing through to margin, which reached an all-time high for the second consecutive quarter of approximately 60%, up sequentially from our previous record of 56%, and that brings our year-to-date margin to 54%. AMTAGVI growth, operational efficiencies, and investment discipline contributed to this margin gain and remain powerful levers for continued expansion as we drive further efficiencies across the company. Turning to operating expenses. Third quarter R&D expenses were down approximately 16% sequentially to about $49 million, marking the fifth consecutive quarter of reduced R&D spend.
This trend reflects efficiency of our operations, including clinical and manufacturing, which allows us to advance multiple registrational programs at greater scale and much less cost than any TIL competitor. Total selling, general, and administrative expenses held flat at about $39 million sequentially, even as revenue grew about 22%. We continue to make targeted investments in revenue-generating activities that drive the greatest commercial return. We are reaffirming our recently updated full-year revenue guidance range of $410 million-$420 million. At the midpoint, that is nearly 60% growth over last year. Through the first three quarters of 2026, we have already delivered $292 million of revenue, expanded margin, and controlled operating expenses. We end the quarter in a strong financial position with approximately $382 million in cash equivalents, short-term investments, and restricted cash on September 30th.
Together, with robust revenue and careful capital allocation, this cash position is now expected to fund operations well into 2029, giving us the runway to execute on our growth plan from a position of strength. In closing, we again delivered strong revenue, improved margin, and intentional capital allocation this quarter. With a strong balance sheet supporting us, we are well-positioned as we build a valuable, self-sustaining business that delivers lasting value for patients and our shareholders. Behind these record results are the patients we serve. For more on how we are reaching them, here is Dan Kirby, our Chief Commercial Officer, to review our commercial progress in more detail.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
